41st week of 2010 patent applcation highlights part 41 |
Patent application number | Title | Published |
20100261662 | UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE - The present disclosure is directed to methods and systems for stabilizing an extracellular matrix in a wall of a blood vessel. The method comprises delivering a therapeutic agent into mural thrombus, which covers the wall of the blood vessel. The agent is transported from the mural thrombus into the extracellular matrix of the vessel wall by diffusion. The agent then acts to reduce the enzymatic degradation of protein in the extracellular matrix. | 2010-10-14 |
20100261663 | Compositions Containing Harpagoside and Paeoniflorin and Methods for Treatment of Conditions Associated with Pain, Inflammation, Arthritis and Symptoms Thereof - The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as pain, inflammation, arthritic conditions and other chronic rheumatic diseases, muscle spasms, and headache, as well as methods for their use. The compositions incorporating purified herbal ingredients can incorporate the following combinations of ingredients: (1) harpagoside and paeoniflorin; (2) harpagoside, paeoniflorin, and bioperin; (3) harpagoside and bioperin; and (4) paeoniflorin and bioperin. | 2010-10-14 |
20100261664 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof - Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | 2010-10-14 |
20100261665 | Kinase inhibitor compounds - The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes. | 2010-10-14 |
20100261666 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYOCARDIAL DYSFUNCTION ASSOCIATED WITH SIRS OR SEPSIS - Provided are compositions and methods for the treatment of myocardial dysfunction associated with SIRS or sepsis, which methods comprise the administration to a patient in need thereof of a composition comprising one or more adenosine deaminase (ADA) inhibitor and/or one or more xanthine oxidase (XO) inhibitor. Exemplified herein are methods for the treatment of myocardial dysfunction, which methods comprise the administration of a composition comprising the ADA inhibitor pentostatin and/or a composition comprising the XO inhibitor allopurinol. Advantageously, the methods disclosed herein that employ the administration of one or more ADA inhibitor(s) do not significantly affect cardiac TNF-α mRNA expression and/or protein levels. | 2010-10-14 |
20100261667 | 3- -D-RIBOFURANOSYLTHIAZOLO[4-5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF - The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds. | 2010-10-14 |
20100261668 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE - Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1). | 2010-10-14 |
20100261669 | UNIT DOSAGE FOR BRAIN HEALTH - The invention pertains to a composition comprising (i) uridine in nucleobase, nucleoside and/or nucleotide form; (ii) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); and (iii) a tocopherol and/or an equivalent thereof, wherein said composition has: a) a weight of 200-3000 mg per unit dose; b) an energy content of less than 50 kcal per unit dose; and/or c) a volume between 0.1 and 10 ml per unit dose. The invention also pertains to the use of such composition in reducing abeta plaque burden and neurodegeneration, in the treatment of diseases related with imparted nerve functioning, in particular dementia, Alzheimer's disease and memory disorders. | 2010-10-14 |
20100261670 | COMPLEXES OF PHOSPHATE DERIVATIVES - There is provided a composition comprising the reaction product of:
| 2010-10-14 |
20100261671 | INULIN PRODUCTS WITH IMPROVED NUTRITIONAL PROPERTIES - The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects/benefits, as well as to their use for the manufacture of consumer products and compositions for providing said effects/benefits in healthy, disfunctioned and diseased humans, mammals and other vertebrates. | 2010-10-14 |
20100261672 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES - A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility. | 2010-10-14 |
20100261673 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME - Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of | 2010-10-14 |
20100261674 | THERAPEUTIC APPLICATIONS OF FATTY ACID AMIDE HYDROLASE INHIBITORS - Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy. | 2010-10-14 |
20100261675 | FUNGICIDAL COMPOSITION CONTAINING ACID AMIDE DERIVATIVE - Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired. The present invention provides a fungicidal composition containing an acid amide derivative of the formula (I) or a salt thereof, as an active ingredient: | 2010-10-14 |
20100261676 | Use of an Endogenous Ligand for Peroxisome Proliferator Activated Receptor Alpha to Treat Liver Disorders - Compositions comprising the peroxisome proliferator-activated receptor alpha (PPARα)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPARα-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals. | 2010-10-14 |
20100261677 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS - The invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein the groups R | 2010-10-14 |
20100261678 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS - The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y | 2010-10-14 |
20100261679 | CSF-1R, Inhibitors, Compositions, and Methods of Use - Disclosed herein are compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof, compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R. | 2010-10-14 |
20100261680 | HERBICIDES CONTAINING SUBSTITUTED THIEN-3-YL-SULPHONYLAMINO(THIO)CARBONYL-TRIAZOLIN(ETHI)ONES - The invention relates to herbicidal compositions, their preparation, and their use for controlling unwanted vegetation. The compositions include an effective amount of an active compound combination that includes: | 2010-10-14 |
20100261681 | ALPHA-CHLORO AND ALPHA-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis and pharmacology of a series of α-substituted methylene phosphonate analogs, in which the α-CH | 2010-10-14 |
20100261682 | Method and Means for the Treatment of Cachexia - The present invention relates to the treatment of cachexia in a mammal by the use of a compound comprising a high density negatively charged domain of vicinally oriented radicals. | 2010-10-14 |
20100261683 | Selective Inhibitors for Cyclin-Dependent Kinases - This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer. | 2010-10-14 |
20100261684 | Pharmaceutical combination of medication to be used by patients presenting with an acute coronary syndrome so as to stop the process and prevent a myocardial infarction - As many as 60% of patients who experience an acute coronary syndrome die before they even reach a hospital or other health care facilities, hence the importance of an effective treatment that the patient can self-administer at the first symptom or sign of an acute coronary syndrome. That treatment needs to act rapidly, to be easy to use, to be effective, to be safe, and readily available. The present invention describes a pharmaceutical combination containing a beta blocker agent, one or more anti-platelet agent(s) and a coronary vaso-dilator agent all included in a dose format to be taken orally or by sublingual spray to prevent myocardial infarction. | 2010-10-14 |
20100261685 | PERSONAL CARE COMPOSITION - A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole. | 2010-10-14 |
20100261687 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS - Object of the present invention are novel substituted compounds of the formula 1, | 2010-10-14 |
20100261688 | STABILIZATION OF OILY SUSPENSIONS COMPRISING HYDROPHOBIC SILICAS - The invention relates to a stabilization of fluid oil-based suspensions comprising a hydrophobic silica, and medicaments based on such suspensions. | 2010-10-14 |
20100261689 | PYRROLO [1,2-C] IMIDAZOLE DERIVATIVES FOR USE IN THE PROPHYLAXIS OR TREATMENT OF CANCER WHICH IS REFRACTORY TO KNOWN CANCER THERAPIES - The present invention mainly aims to provide a drug for the prophylaxis or treatment of androgen-independent prostate cancer, which is highly useful as a pharmaceutical agent. | 2010-10-14 |
20100261690 | NOVEL COMBINATIONS - The invention provides a pharmaceutical product comprising, in combination, (1) a named glucocorticosteroid receptor agonist and (2) a β | 2010-10-14 |
20100261691 | AMORPHOUS FORM OF AN ANTI-INFLAMMATORY COMPOUND - The invention relates to the technical field of anti-inflammatory compounds, specifically those of a steroid nature, in particular to a new amorphous form of a nitrooxy derivative of a corticosteroid, its pharmaceutical formulations and its use in the treatment or prevention of diseases or symptoms of the skin or mucous membranes. | 2010-10-14 |
20100261692 | METHOD OF MANUFACTURE OF COMPRESSED PHARMACEUTICAL FORMULATION CONTAINING TIBOLONE - Method of manufacture of compressed pharmaceutical formulation with the active substance tibolone by direct compression into tablets, whereas during the manufacturing process the formulation is subjected to the action of a protic solvent, either by addition of 0.1 to 3% by weight of said solvent in the liquid state and/or in the vapor form by ensuring the ambient atmosphere with the contents of solvent vapors above 50% relative. | 2010-10-14 |
20100261693 | METHOD FOR TREATING CUSHING'S SYNDROME - The invention relates to a method for treating Cushing's syndrome in a patient, which method comprises administering the patient with a pharmaceutical composition comprising a glucocorticoid receptor antagonist, at least twice a day, or an extended-release composition of a glucocorticoid receptor antagonist, or a combination of a glucocorticoid receptor antagonist and a inhibitor of cortisol synthesis. | 2010-10-14 |
20100261694 | Chemical chaperones and methods of use thereof for inhibiting proliferation of the phytopathogenic fungus Fusarium ssp. - Compositions and methods for preventing | 2010-10-14 |
20100261695 | TREATMENT OF ONYCHOMYCOSIS AND RELATED COMPOSITIONS - The present invention generally relates to the treatment of onychomycosis. More specifically, it relates to combination therapies for the treatment of onychomycosis and related compositions. In a composition aspect, the present invention provides a composition for the treatment of onychomycosis, wherein the composition includes Ciclopirox and at least one other antifungal agent. In a method aspect, the present invention provides a method for treating onychomycosis in a patient suffering from the disease. The method involves topically administering a composition to at least one toe or fingernail of the patient and the composition includes Ciclopirox and at least one other antifungal agent. | 2010-10-14 |
20100261696 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS - In one aspect, the invention relates to compounds which are useful as as inhibitors of glycine type 1 transporter (G1yT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with glycine type 1 transporter (G1yT1) activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2010-10-14 |
20100261697 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES - Compounds of the formula (I) in which R | 2010-10-14 |
20100261698 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula I: | 2010-10-14 |
20100261699 | N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE - The present invention relates to a compound represented by the formula: | 2010-10-14 |
20100261700 | BETA-LACTAMASE INHIBITORS - Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections. | 2010-10-14 |
20100261701 | 8-Substituted isoquinoline derivative and the use thereof - The present invention relates to a compound represented by the following formula (1): | 2010-10-14 |
20100261702 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 - The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I). | 2010-10-14 |
20100261703 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG - A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 2010-10-14 |
20100261704 | THERAPEUTIC AGENTS 928 - A compound (2S)-2-[1-(2,6-dichlorophenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-(3-hydroxyazetidin-1-yl)-N-(5-methylpyrazin-2-yl)propanamide is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion. | 2010-10-14 |
20100261705 | CARBOSTYRIL COMPOUND - The present invention provides a carbostyril compound represented by General Formula (1) | 2010-10-14 |
20100261706 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF - Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative. | 2010-10-14 |
20100261707 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives. | 2010-10-14 |
20100261708 | Diazepane Compounds Which Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 2010-10-14 |
20100261709 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS - The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinaldamage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment. | 2010-10-14 |
20100261710 | HDAC Inhibitors - The present invention provides hydroxamic acid compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the hydroxamic acid compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention. | 2010-10-14 |
20100261711 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES - In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of seizures. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of seizures with reduced sedative and ataxic side effects. | 2010-10-14 |
20100261712 | HEMATOPOIETIC NEOPLASM CHEMOTHERAPY - A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided. | 2010-10-14 |
20100261713 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 2010-10-14 |
20100261714 | INHIBITORS OF HIV REPLICATION - Compounds of formula (I): | 2010-10-14 |
20100261715 | CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 - Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. | 2010-10-14 |
20100261716 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel indazole-carboxamide 5-HT | 2010-10-14 |
20100261717 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS - Disclosed are compounds of the Formula I | 2010-10-14 |
20100261718 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS - Disclosed are compounds of the Formula | 2010-10-14 |
20100261719 | CHEMICAL COMPOUNDS - In one aspect, the present invention relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, wherein: n is 1 to 4; and R | 2010-10-14 |
20100261720 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides a heterocyclic compound represented by General Formula (1): | 2010-10-14 |
20100261721 | Novel Sulphonylpyrroles - Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. | 2010-10-14 |
20100261722 | HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES - HIV replication inhibitors of formula | 2010-10-14 |
20100261723 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES - A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme. | 2010-10-14 |
20100261724 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to heterocycle phenyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 2010-10-14 |
20100261725 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2010-10-14 |
20100261726 | TREATMENT OF AML - The present invention relates to a method of treating a warm-blooded animal having acute myeloid leukemia (AML) which is resistant to conventional chemotherapy, comprising administering to said animal a therapeutically effective amount of a compound of formula I | 2010-10-14 |
20100261727 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT - 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: | 2010-10-14 |
20100261728 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS - Tetrahydroisoquinoline compounds of formula (I), and compositions containing them, for the treatment of acute, inflammatory and neurophatic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neurophatic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. | 2010-10-14 |
20100261730 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME - The invention relates to alkynylaryl compounds according to the general formula (I) in which A, B, D, E, R | 2010-10-14 |
20100261731 | Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate - The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir. | 2010-10-14 |
20100261732 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS - The invention relates to novel 5-hydroxytryptamine (5-HT) receptor modulator compounds of formula (I); wherein A, B, R | 2010-10-14 |
20100261733 | THERAPEUTIC AGENTS 927 - (2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion. | 2010-10-14 |
20100261734 | Methods of Treating Bladder Dysfunction Using Netupitant - The present invention relates to methods for reducing the frequency of bladder contractions without significantly affecting micturition pressure, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt or prodrug thereof. The method can be used to treat bladder dysfunction without significantly increasing residual volume, including urgency, frequency, pollakiuria, nocturia, low deferment time, suboptimal volume threshold, neurogenic bladder, or combinations thereof. | 2010-10-14 |
20100261735 | FUNGICIDAL COMPOSITION CONTAINING ACID AMIDE DERIVATIVE - Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired. The present invention provides a fungicidal composition containing an acid amide derivative of the formula (I) or a salt thereof, as an active ingredient: | 2010-10-14 |
20100261736 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE - The present application relates to novel substituted bicyclic heteroaryl compounds, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases. | 2010-10-14 |
20100261738 | NOVEL POLYMORPHS OF ERLOTINIB HYDROCHLORIDE AND METHOD OF PREPARATION - The present invention relates to three novel crystalline forms of Erlotinib hydrochloride and method of preparation thereof. Erlotinib hydrochloride is N-(3-ethynylphenyl)-6,7-bis(2-methoxy ethoxy)-4-quinazolinamine hydrochloride of formula-(I). The present invention provides stable novel crystalline forms of Erlotinib hydrochloride designated as Form-M, Form-N and Form-P, and processes for the preparation of the same. Erlotinib hydrochloride can be used as medicament for the treatment of hyperproliferative disorders, such as cancers, in humans. | 2010-10-14 |
20100261739 | Method of Treating Non-Small Cell Lung Cancer - A method of treating non-small cell lung cancer (NSCLC), and especially NSCLC that has metastasized to brain is disclosed. | 2010-10-14 |
20100261740 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT - The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted 4-(tetrazol-5-yl)-quinazoline derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man. | 2010-10-14 |
20100261741 | Quinazolinone T-Type Calcium Channel Antagonists - The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 2010-10-14 |
20100261742 | NOVEL POLYMORPHIC FORMS - Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed. | 2010-10-14 |
20100261743 | NOVEL SEH INHIBITORS AND THEIR USE - The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: | 2010-10-14 |
20100261744 | PHARMACEUTICAL FORMULATION - Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided. | 2010-10-14 |
20100261745 | PHARMACEUTICAL FORMULATION - Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided. | 2010-10-14 |
20100261746 | PHARMACEUTICAL FORMULATION - Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided. | 2010-10-14 |
20100261747 | NOVEL PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE - The present invention provides a standardized method for the detection of narcotic abuse. Narcotics are formulated with a test compound that is not completely metabolized by the body. Narcotic diversion is detected by urinalysis of the suspected abuser, wherein the test compound may be detected even if the diverted narcotic is completely metabolized by the body, or otherwise undetectable in the urine. | 2010-10-14 |
20100261748 | STABLE LORATADINE SPILL RESISTANT FORMULATION - The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension. | 2010-10-14 |
20100261749 | METHOD OF PREVENTING OR AMELIORATING PSORIASIS USING PYRROLOQUINOLINE QUINONE COMPOUNDS - It is an object of the present invention to provide a safe and highly effective preventing or ameliorating agent for skin psoriasis. | 2010-10-14 |
20100261750 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2010-10-14 |
20100261751 | METHOD FOR DETERMINING ONE OF THE TWO HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE ENZYMATIC ACTIVITIES - The invention concerns a method for determining one of the two Human Immunodeficiency Virus (HIV) integrase enzymatic activities, in particular 3′-end processing, in an in vitro assay. | 2010-10-14 |
20100261752 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS - The invention provides methods for the treatment of cognitive disorders utilizing specific 5-HT | 2010-10-14 |
20100261753 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM - The present invention provides methods for preventing and/or treating degenerative disorders of the central nervous system using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease. | 2010-10-14 |
20100261754 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS - The invention relates to compounds corresponding to general formula (I) below: | 2010-10-14 |
20100261755 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS - or a pharmaceutically suitable salt thereof, wherein,
| 2010-10-14 |
20100261756 | METHOD FOR INHIBITING PLATELET AGGREGATION - A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof. | 2010-10-14 |
20100261757 | Insecticidal (Heteroarylalky)alkane Thio and Oxo Amine Derivatives - Certain novel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, b, c, T, W, Y R, R | 2010-10-14 |
20100261758 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS - Compounds of Formula (I) wherein R | 2010-10-14 |
20100261759 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE - The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders. | 2010-10-14 |
20100261760 | EP2 Receptor Agonists - The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor. | 2010-10-14 |
20100261761 | Novel Sulfonylpyrroles - Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. | 2010-10-14 |
20100261762 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR - A serotonin and norepinephrine reuptake inhibitor of the formula: | 2010-10-14 |
20100261763 | ANTIBACTERIAL AGENTS AND METHODS OF USE THEREOF - The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alky groups, and optionally having hydroxyl and/or alkoxyl groups substituents. | 2010-10-14 |
20100261764 | SUBSTITUTED 3 -HYDROXYPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to novel therapeutic compounds of formula (I) wherein R | 2010-10-14 |